Loading…
Makes automated cell counting instruments used in biopharma research, bioprocessing and IVF labs.
Makes automated cell counting instruments used in biopharma research, bioprocessing and IVF labs.
Sells counting instruments and then earns repeatedly from the disposable cassettes each test needs, so every installed machine keeps generating consumable orders. Most of the business is exported, through distributors and direct sales to customers across Europe, the US and Asia.
Moat: narrow (switching costs, IP / patents, installed base). Installed instrument base drives recurring high-margin consumable sales; validated workflows are sticky.
Headquarters: Allerod, Denmark · Founded: 1997 · Employees: 174
Size ChemoMetec A/S (CHEMM.CO) is a Denmark Health Care company (Medical Specialties) with a market value of $1.69B, the 37th largest of 59 Denmark companies the cockpit tracks. Shares closed at DKK 706.00 on 6 Nov 2026.
Performance Over six months the shares gained 124.3%, against -4.7% for the median peer and +8.8% for the Denmark market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +12.4%); the operating margin is 49.1% (peer median 10.9%).
Valuation It trades at 52.0× forward earnings against a peer median of 24.9× (4th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 38.0 points above its cost of capital (6.8% WACC).
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | DKK 511M | DKK 511M | DKK 496M | DKK 407M | DKK 442M |
| Revenue growth | — | +3% | +22% | -8% | — |
| Gross profit | DKK 329M | DKK 329M | DKK 300M | DKK 222M | DKK 280M |
| EBITDA | DKK 266M | DKK 266M | DKK 248M | DKK 178M | DKK 242M |
| Net income | DKK 202M | DKK 202M | DKK 175M | DKK 136M | DKK 179M |
| Free cash flow | DKK 182M | DKK 182M | DKK 178M | DKK 108M | DKK 133M |
| Capital expenditure | DKK 96.4M | DKK 96.4M | DKK 64.7M | DKK 43.5M | DKK 40.8M |
| Total debt | n/a | DKK 4.59M | DKK 6.40M | DKK 4.16M | DKK 7.16M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ChemoMetec A/S CHEMM.CO | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Sartorius SRT.DE | $20.0B | +34% | +4% | 18% | 42.6× | 24.9% |
| Bio-Rad Laboratories BIO | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CHEMM.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +27.1% | +0.3% | 4th highest of 21 |
| 6-month return | +124.3% | -4.7% | highest of 20 |
| Distance from 52-week high | -11.4% | -22.1% | 4th highest of 21 |
| Revenue growth (TTM) | +3.1% | +12.4% | 5th lowest of 21 |
| Operating margin | 49.1% | 10.9% | highest of 21 |
| Forward P/E | 52.0× | 24.9× | 4th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 17.9% | 8.7% | 5th most demanding of 13 |
| Growth delivered (Del g) | +12.7% | +14.3% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | +5.2 pp | -6.5 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | +38.0 pp | +0.6 pp | highest of 21 |
| EV / EBITDA | 41.1× | 15.8× | 3rd most expensive of 12 |
| Net debt / EBITDA | -1.1× | 0.9× | 4th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 20.4× | 18.8% | +14.5% |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | n/a | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |